Topics

Incyte Corporation and AstraZeneca Company Profile

02:59 EST 24th January 2020 | BioPortfolio


News Articles [893 Associated News Articles listed on BioPortfolio]

After AstraZeneca, Osbourn Reflects on Roles at CAT & MedImmune

MedImmune, AstraZeneca’s biologics division, is no more. The pharmaceutical giant announced last year that the name would be retired as part of a research and development restructuring. Before MedIm...

AstraZeneca spends £750 million on new HQ

AstraZeneca’s new headquarters in Cambridge, United Kingdom are expected to cost more than double the sum of £330 million that the firm budgeted for in 2013. At a cost of £750 million so far, Astr...

AstraZeneca spends more than twice as much as expected on new HQ

AstraZeneca’s new headquarters in Cambridge, United Kingdom are expected to cost more than double the sum of £330 million that the firm budgeted for in 2013. At a cost of £750 million so far, Astr...

1,767 Orion Corporation A shares converted into B shares

ORION CORPORATION STOCK EXCHANGE RELEASE 19 JUNE 2019 at 9.30 EEST                      1,767 Orion Corporation A shares converted into B shares In accordance wit...

AstraZeneca BioVenture Hub: A new way of building companies fast

Magus Bjorsne, CEO of AstraZeneca's BioVenture Hub, discusses how the capability, experience and expertise of AstraZeneca in helping mature Biotechs transition into product development.

Change in Orion Corporation's holding of treasury shares

ORION CORPORATION STOCK EXCHANGE RELEASE 11 JUNE 2019 at 11.45 EEST                      Change in Orion Corporation's holding of treasury shares A total of ...

Tim Herpin, AstraZeneca: Achieving scientific leadership and restoring growth

In this interview filmed at BIO Europe in Vienna, Paul Larsmon talks to Tim Herpin, Vice President, Head of transactions, Business development, GPPS, AstraZeneca. They discuss the change in strategy a...

AstraZeneca Gets Full Responsibility For Commercialising Linzess In China

LONDON (dpa-AFX) - AstraZeneca (AZN.L, AZN) said that it has amended its collaboration agreement with Ironwood Pharmaceuticals. The amended agreement gives AstraZeneca sole responsibility for deve...

Drugs and Medications [85 Associated Drugs and Medications listed on BioPortfolio]

Sodium citrate blood-pack units, (pl 146 plastic) [fenwal, inc.]

Sodium citrate blood-pack units, (pl 146 plastic) [fenwal, inc.]

Rosuvastatin [apotex corp.]

These highlights do not include all the information needed to use ROSUVASTATIN CALCIUM TABLETS safely and effectively. See full prescribing information for ROSUVASTATIN CALCIUM TABLETS. ROSUVASTATIN C...

Rosuvastatin [apotex corp.]

These highlights do not include all the information needed to use ROSUVASTATIN CALCIUM TABLETS safely and effectively. See full prescribing information for ROSUVASTATIN CALCIUM TABLETS. ROSUVASTATIN C...

Oxygen [medox corporation ]

Oxygen

PubMed Articles [5 Associated PubMed Articles listed on BioPortfolio]

Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).

Antiangiogenic agents combined with chemotherapy have efficacy in the treatment of unresectable malignant pleural mesothelioma (MPM). Cediranib (AstraZeneca, Cheshire, United Kingdom), a vascular endo...

The Future Of Omics For Clinical Practice.

Dr. Kari Nadeau: Dr. Nadeau receives grant support from NIAID, Food Allergy Research & Education (FARE), End Allergies Together, Allergenis, Ukko; personal Fees from Regeneron, AstraZeneca, ImmuneWork...

Oral Corticosteroid Use for the Treatment of Chronic Eosinophilic Disease: A Patient's and His Physician's Experience.

This article, coauthored by a patient with eosinophilic granulomatosis with polyangiitis (EGPA) initially presenting as severe eosinophilic asthma and his physician-specialist, discusses the use and m...

The Effectiveness and Value of Treatments for Spinal Muscular Atrophy.

Funding for this summary was contributed by the Laura and John Arnold Foundation and California Health Care Foundation to the Institute for Clinical and Economic Review (ICER), an independent organiza...

Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.

Diabetes-related complications including cardiovascular disease, heart failure (HF), chronic kidney disease, retinopathy, and neuropathy are associated with a high burden of disease. Early initiation ...

Clinical Trials [47 Associated Clinical Trials listed on BioPortfolio]

Pharmacokinetics, Safety and Tolerability of CKD-387 10/500mg BE Phase1

The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of CKD-387

Clinical Study, Non Inferiority Between Noex® 32µg Versus Budecort Aqua® 32µg in Treatment of Alergic Rhinitis

This study is to evaluate non inferiority of Eurofarma budesonide nasal spary x referral Astrazeneca budesonide. Half patients will receive Eurofarma medication and half patients will rece...

Bio Equivalence Study of Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets Under Fasting Condition.

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Esomeprazole Magnesium DR Capsules Under Fasting Conditions

Subjects to compare the single dose bioavailability of Torrent's Esomeprazole Magnesium DR Capsules 40 mg and Nexium® 40 mg DR Capsules of AstraZeneca LP, USA. Dosing periods of studies w...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Companies [261 Associated Companies listed on BioPortfolio]

AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestin...

AstraZeneca Pharmaceuticals LP

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a lead...

AstraZeneca and The Medicines Company

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastro...

AstraZeneca HealthCare Foundation

Established in 1993, the AstraZeneca HealthCare Foundation is a Delaware not-for-profit corporation and a 501(c)(3) entity organized for charitable purposes including to promote p...

AstraZeneca AS

AstraZeneca er et av verdens ledende farmasøytiske selskaper. Vi bruker hvert år ca. 25 milliarder norske kroner på forskning verden over for å utvikle nye medisiner. Dette har resultert i en rekk...

More Information about "Incyte Corporation and AstraZeneca" on BioPortfolio

We have published hundreds of Incyte Corporation and AstraZeneca news stories on BioPortfolio along with dozens of Incyte Corporation and AstraZeneca Clinical Trials and PubMed Articles about Incyte Corporation and AstraZeneca for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Incyte Corporation and AstraZeneca Companies in our database. You can also find out about relevant Incyte Corporation and AstraZeneca Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record